Trim family and tumor

doi:10.3760/cma.j.issn.1673-422X.2015.06.011

Abstract

Abstract: Studies show that some Trim family proteins are associated with tumorigenesis and cancer progression. Trim members are differently expressed in various cancers including lung cancer, hepatocellular carcinoma, colon cancer, stomach cancer and breast cancer. Trim proteins are found to be involved in tumor progess by modulating the expression of tumor associated genes via several signaling pathways such as p53 and NFκB pathway. Members of Trim family can be used as oncogenes or antioncogenes in the biological processes such as tumor cell proliferation, cell differentiation, cell apoptosis and metastasis.

Key words: Ubiquitination, Neoplasms, Genes, p53, Tripartite motif protein

Yang Qingmei, Xu Zumin, Guan Chengnong. Trim family and tumor[J]. Journal of International Oncology, 2015, 42(6): 442-444.

References

［1］ Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment［J］. Nat Med, 2014, 20(11): 1242-1253. ［2］ Micale L, Chaignat E, Fusco C, et al. The tripartite motif: structure and function［J］. Adv Exp Med Biol, 2012, 770: 11-25. ［3］ Ozato K, Shin DM, Chang TH, et al. TRIM family proteins and their emerging roles in innate immunity［J］. Nat Rev Immunol, 2008, 8(11): 849-860. ［4］ Meroni G, DiezRoux G. TRIM/RBCC, a novel class of ′single protein RING finger′ E3 ubiquitin ligases［J］. Bioessays, 2005, 27(11): 1147-1157. ［5］ Khetchoumian K, Teletin M, Tisserand J, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha［J］. Nat Genet, 2007, 39(12): 1500-1506. ［6］ Chambon M, Orsetti B, Berthe ML, et al. Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer［J］. Am J Pathol, 2011, 178(4): 1461-1469. ［7］ Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a noncanonical histone signature to breast cancer［J］. Nature, 2010, 468(7326): 927-932. ［8］ Kikuchi M, Okumura F, Tsukiyama T, et al. TRIM24 mediates liganddependent activation of androgen receptor and is repressed by a bromodomaincontaining protein, BRD7, in prostate cancer cells［J］. Biochim Biophys Acta, 2009, 1793(12): 1828-1836. ［9］ Ryu YS, Lee Y, Lee KW, et al. TRIM32 protein sensitizes cells to tumor necrosis factor (TNFα)induced apoptosis via its RING domaindependent E3 ligase activity against Xlinked inhibitor of apoptosis (XIAP)［J］. J Biol Chem, 2011, 286(29): 25729-25738. ［10］ Horn EJ, Albor A, Liu Y, et al. RING protein Trim32 associated with skin carcinogenesis has antiapoptotic and E3ubiquitin ligase properties［J］. Carcinogenesis, 2004, 25(2): 157-167. ［11］ Kano S, Miyajima N, Fukuda S, et al. Tripartite motif protein 32 facilitates cell growth and migration via degradation of Ablinteractor 2［J］. Cancer Res, 2008, 68(14): 5572-5580. ［12］ Liu J, Zhang C, Wang XL, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis［J］. Cell Death Differ, 2014, 21(11): 1792-1804. ［13］ Fitzgerald S, Sheehan KM, O′Grady A, et al. Relationship between epithelial and stromal TRIM28 expression predicts survival in colorectal cancer patients［J］. J Gastroenterol Hepatol, 2013, 28(6): 967-974. ［14］ Chen L, Chen DT, Kurtyka C, et al. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions［J］. J Biol Chem, 2012, 287(48): 40106-40118. ［15］ Chen L, MunozAntonia T, Cress WD. Trim28 contributes to EMT via regulation of Ecadherin and Ncadherin in lung cancer cell lines［J］. PloS One, 2014, 9(7): e101040. ［16］ Sho T, Tsukiyama, Sato t, et al. TRIM29 negatively regulates p53 via inhibition of Tip60［J］. Biochim Biophys Acta, 2014, 1813(6): 1245-1253. ［17］ Sun H, Dai X, Han B. TRIM29 as a novel biomarker in pancreatic adebocarnoma［J］. Dis Markers, 2014, 2014: 317817. ［18］ Zhou ZY, Yang GY, Zhou J, et al. Significance of TRIM29 and β-catenin expression in nonsmallcell lung cancer［J］. J Chin Med Assoc, 2012, 75(6): 269-274. ［19］ Hawthorn L, Stein L, Panzarella J, et al. Characterization of celltype specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung［J］. Lung Cancer, 2006, 53(2): 129-142. ［20］ Fristrup N, BirkenkampDemtroder K, Reinert T, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in nonmuscleinvasive bladder cancer［J］. Am J Pathol, 2013, 182(2): 339-349 . ［21］ Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy［J］. Int J Cancer, 2004, 112(1): 14-25. ［22］ Katkoori VR, Shanmugam C, Jia X, et al. Prognostic significance and gene expression profiles of p53 mutations in microsatellitestable stage Ⅲ colorectal adenocarcinomas［J］. PLoS One, 2012, 7(1): e30020. ［23］ Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells［J］. Blood, 2002, 99(5): 1745-1757. ［24］ Kosaka Y, Inoue H, Ohmachi T, et al. Tripartite motifcontaining 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer［J］. Ann Surg Oncol, 2007, 14(9): 2543-2549. ［25］ Horio M, Kato T, Mii S, et al. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer［J］. Cancer Med, 2012, 1(2):218-229. ［26］ Iwakoshi A, Murakumo Y, Kato T, et al. RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations［J］. Pathol Int, 2012, 62(5): 324-330. ［27］ Tsukamoto H, Kato T, Enomoto A, et al. Expression of Ret finger protein correlates with outcomes in endometrial cancer［J］. Cancer Sci, 2009, 100(10): 1895-1901. ［28］ Tomar D, Sripada L, Prajapati P, et al. Nucleocytoplasmic trafficking of TRIM8, a novel oncogene, is involved in positive regulation of TNF induced NFκB pathway［J］. PLoS One, 2012, 7(11): e48662. ［29］ Caratozzolo MF, Valletti A, Gigante M, et al. TRIM8 antiproliferative action against chemoresistant renal cell carcinoma［J］. Oncotarget, 2014, 5(17): 7446-7457.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.